High-resolution breakpoint mapping by Optical Genome Mapping enables precise detection of clinically actionable gene rearrangements in acute lymphoblastic leukemia (ALL), including MEF2D::CSF1R and PAX5::JAK2 fusions—hallmarks of the Philadelphia-like (Ph-like) ALL subtype. The gene discussed is MEF2D; the disease is acute lymphoblastic leukemia.